Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy - 2026
Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy
Powell, Matthew A.; Ghamande, Sharad; Hanker, Lars C.et al.
2026 • In International Journal of Gynecological Cancer, p. 104774
Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834
Guo F, Adekanmbi V, Hsu CD, et al. Trends in endometrial cancer incidence among premenopausal and postmenopausal women in the United States between 2001 and 2021. Cancers. 2025;17(6):1035. doi:10.3390/cancers17061035
Ren Y, Xu R, Wang Y, Su L, Su J. Global, regional, and national burden of ovarian cancer in women aged 45+from 1990 to 2021 and projections for 2050: a systematic analysis based on the 2021 global burden of disease study. J Cancer Res Clin Oncol. 2025;151(8):225. doi:10.1007/s00432-025-06277-9
Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22(11):2159-2166. doi:10.1200/JCO.2004.07.184
Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). J Clin Oncol. 2020;38(33):3841-3850. doi:10.1200/JCO.20.01076
Oaknin A, Bosse TJ, Creutzberg CL, et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(9):860-877. doi:10.1016/j.annonc.2022.05.009
Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med. 2023;388(23):2145-2158. doi:10.1056/NEJMoa2216334
Powell MA, Bjoerge L, Willmott L, et al. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. Ann Oncol. 2024;35(8):728-738. doi:10.1016/j.annonc.2024.05.546
Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023;388(23):2159-2170. doi:10.1056/NEJMoa2302312
Westin SN, Moore K, Chon HS, et al. Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial. J Clin Oncol. 2024;42(3):283-299. doi:10.1200/JCO.23.02132
Concin N, Matias-Guiu X, Cibula D, et al. ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025. Lancet Oncol. 2025;26(8):e423-e435. doi:10.1016/S1470-2045(25)00167-6
Francoeur AA, Ayoub N, Greenberg D, Tewari KS. Drug discovery in advanced and recurrent endometrial cancer: recent advances. Oncol Res. 2025;33(7):1511-1530. doi:10.32604/or.2025.061120
Disis ML, Adams SF, Bajpai J, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer. J Immunother Cancer. 2023;11(6):e006624. doi:10.1136/jitc-2022-006624
Costa BV, Vale N. Dostarlimab: a review. Biomolecules. 2022;12(8):1031. doi:10.3390/biom12081031
Jemperli product information. GSK. Accessed February 2, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s009lbl.pdf.
Jemperli summary of product characteristics. GSK. Accessed February 2, 2026. https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf.
Fernandes I, Chehade R, MacKay H. PARP inhibitors in non-ovarian gynecologic cancers. Ther Adv Med Oncol. 2024;16:17588359241255174. doi:10.1177/17588359241255174
O’Malley DM, Krivak TC, Kabil N, Munley J, Moore KN. PARP inhibitors in ovarian cancer: a review. Target Oncol. 2023;18(4):471-503. doi:10.1007/s11523-023-00970-w
Rao Y, Zhang W, Zhang N, Han H, Xiao Y, Liu P. Prevalence of homologous recombination deficiency in different molecular subgroups of endometrial carcinomas. J Clin Oncol. 2025;43(suppl 16):e17631. doi:10.1200/JCO.2025.43.16_suppl.e17631
Shen M, Lin Y, Yao Z, Lin L, Sun Y. 16P Homologous recombination deficiency in endometrial cancer: association with clinical and molecular characteristics. ESMO Open. 2024;9:103516. doi:10.1016/j.esmoop.2024.103516
Arcieri M, Tius V, Andreetta C, et al. How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature. Front Oncol. 2024;14:1335196. doi:10.3389.fonc.2024/1335196
Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D’Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5(11):1137-1154. doi:10.1158/2159-8290.CD-15-0714
Musacchio L, Caruso G, Pisano C, et al. PARP inhibitors in endometrial cancer: current status and perspectives. Cancer Manag Res. 2020;12:6123-6135. doi:10.2147/CMAR.S221001
Wanderley CWS, Correa TS, Scaranti M, Cunha FQ, Barroso-Sousa R. Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications. Front Immunol. 2022;13:816642. doi:10.3389/fimmu.2022.816642
Stewart RA, Pilie PG, Yap TA. Development of PARP and immune-checkpoint inhibitor combinations. Cancer Res. 2018;78(24):6717-6725. doi:10.1158/0008-5472.CAN-18-2652
Wang J, Aroumougame A, Lobrich M, et al. PTIP associates with Artemis to dictate DNA repair pathway choice. Genes Dev. 2014;28(24):2693-2698. doi:10.1101/gad.252478.114
Wang N, Yang Y, Jin D, et al. PARP inhibitor resistance in breast and gynecological cancer: resistance mechanisms and combination therapy strategies. Front Pharmacol. 2022;13:967633. doi:10.3389/fphar.2022.967633
Post CCB, Westermann AM, Boere IA, et al. Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial). Gynecol Oncol. 2022;165(2):223-229. doi:10.1016/j.ygyno.2022.02.025
Joly F, Leary A, Ray-Coquard I, et al. Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial. Nat Commun. 2025;16(1):7950. doi:10.1038/s41467-025-62678-x
Piffoux M, Leary A, Follana P, et al. Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial. Nat Commun. 2025;16(1):1821. doi:10.1038/s41467-025-56914-7
GSK. A study to evaluate dostarlimab plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel in participants with recurrent or primary advanced endometrial cancer (RUBY). ClinicalTrials.gov. Accessed December 14, 2025. https://clinicaltrials.gov/study/NCT03981796.
Imfinzi. Summary of product characteristics. Astra Zeneca. Accessed February 2, 2026. https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf.
Imfinzi: prescribing information. Astra Zeneca. Accessed February 2, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761069s050lbl.pdf.
Zhang H, Yan G, Yan J, Zeng X. Efficacy and safety of PARP inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis. Front Immunol. 2025;16:1659650. doi:10.3389/fimmu.2025.1659650
Corr BR, Haggerty A, Gysler SM, et al. A phase II, randomized, double-blind study of the use of Rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer. Gynecol Oncol. 2025;200:58-67. doi:10.1016/j.ygyno.2025.07.008
Siedel JH, Ring KL, Hu W, et al. Clinical significance of homologous recombination deficiency score testing in endometrial cancer. Gynecol Oncol. 2021;160(3):777-785. doi:10.1016/j.ygyno.2020.12.010
Heeke AL, Pishvaian MJ, Lynce F, et al. Prevalence of homologous recombination-related gene mutations across multiple cancer types. JCO Precis Oncol. 2018;2018(2):1-13. doi:10.1200/PO.17.00286
Su CT, Nizialek E, Berchuck JE, et al. Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer. Prostate. 2023;83(3):227-236. doi:10.1002/pros.24454
Merry E, Gourley C. Targeting DNA damage repair pathways beyond PARP inhibition. Target Oncol. 2025;20(6):937-953. doi:10.1007/s11523-025-01183-z
Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nat Med. 2025;31(5):1539-1546. doi:10.1038/s41591-025-03566-1
Van Nieuwenhuysen E, Chon HS, Pepin JT, et al. 40MO first-line (1L) durvalumab+carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib for endometrial cancer (EC) (DUO-E): objective response rate (ORR), duration of response (DoR) and time to treatment discontinuation or death (TDT) by mismatch repair (MMR) status. ESMO Open. 2024;9:103540. doi:10.1016/j.esmoop.2024.103540
Arciuolo D, Travaglino A, Raffone A, et al. TCGA molecular prognostic groups of endometrial carcinoma: current knowledge and future perspectives. Int J Mol Sci. 2022;23(19):11684. doi:10.3390/ijms231911684
Kommoss S, McConechy MK, Kommoss F, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018;29(5):1180-1188. doi:10.1093/annonc/mdy058
Villacampa G, Eminowicz G, Navarro V, et al. Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: a systematic review and network meta-analysis. Eur J Cancer. 2025;220:115329. doi:10.1016/j.ejca.2025.115329
